Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Conditions
Interventions
IMO-8400 Dose Group 1
IMO-8400 Dose Group 2
+1 more
Locations
20
United States
University of Alabama
Birmingham, Alabama, United States
Phoenix Neurological Associates
Phoenix, Arizona, United States
University of California, Irvine
Irvine, California, United States
Stanford Hospital and Clinics
Stanford, California, United States
George Washington University
Washington D.C., District of Columbia, United States
University of Miami
Miami, Florida, United States
Start Date
November 1, 2015
Primary Completion Date
May 16, 2018
Completion Date
June 1, 2018
Last Updated
October 10, 2019
NCT04402086
NCT07160205
NCT07374107
NCT07089121
NCT06371417
NCT02945345
Lead Sponsor
Idera Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions